...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: you won’t see anyone buying this

"over the last 2 years alone. That means every royalty distribution will be more than 1/3 less forever."

every chance these folks get they have done nothing but line their pockets at the lowest possible levels available! We may all see a tiny piece of the pie but their making dam sure they feast on the majority of it! Crooked imo.

Share
New Message
Please login to post a reply